Platelet activation and thrombosis pathway

The platelet activation and thrombosis pathway is a multi-step biological process critical for maintaining vascular integrity through hemostasis, yet it is also the primary driver of pathological arterial thrombosis [1]. The process begins with platelet adhesion to subendothelial proteins like collagen and von Willebrand factor following vascular injury, followed by the release of secondary mediators such as adenosine diphosphate (ADP) and thromboxane A2 [2]. These mediators amplify the response, leading to the activation of the glycoprotein IIb/IIIa receptor, which facilitates platelet-to-platelet aggregation via fibrinogen bridging [3]. In the context of atherosclerotic plaque rupture, this pathway becomes hyperactive, forming thrombi that can occlude coronary or cerebral arteries, resulting in myocardial infarction or stroke [4]. Therapeutic strategies targeting this pathway include a variety of antiplatelet drugs that inhibit specific signaling nodes, such as COX-1 or P2Y12 receptors, to reduce the risk of major adverse cardiovascular events [5]. However, because these drugs interfere with the essential process of clot formation, the primary clinical challenge is balancing antithrombotic efficacy with the inherent risk of life-threatening bleeding [6]. References: [1] StatPearls: Physiology, Platelet (https://www.ncbi.nlm.nih.gov/books/NBK545142/) [2] NIH: Platelet Activation and Aggregation (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3076485/) [3] PubMed: The role of platelets in arterial thrombosis (https://pubmed.ncbi.nlm.nih.gov/21903444/) [4] Journal of the American College of Cardiology: Antiplatelet Therapy in Cardiovascular Disease (https://www.jacc.org/doi/10.1016/j.jacc.2019.09.011) [5] Nature Reviews Drug Discovery: Targeting platelet receptors (https://www.nature.com/articles/nrd2245) [6] Circulation: Bleeding Risk of Antiplatelet Therapy (https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.117.028309)

Other names

Platelet activation pathwayThrombotic pathwayHemostatic pathwayPlatelet aggregation cascadePlatelet activation/thrombosis pathway

Inhibition of cyclooxygenase-1 (COX-1), antagonism of P2Y12 purinergic receptors, inhibition of Glycoprotein IIb/IIIa receptors, and antagonism of Protease-activated receptor-1 (PAR-1) [4][5].